Melanoma
Conference Coverage
Lenvatinib combo may offer hope after immunotherapy in melanoma
From the Journals
Durable response 5 years after adjuvant combo in melanoma
Plateaus observed with relapse and distant metastasis-free survival suggest that true disease cures are being achieved with treatment.
From the Journals
Fatal pediatric melanomas diverse in presentation
One-fourth of fatal pediatric melanomas arose in association with congenital melanocytic nevi.
Latest News
Melanoma experts say ‘no’ to routine gene profile testing
This test is not endorsed by the American Academy of Dermatology or National Comprehensive Cancer Network outside of studies.
From the Journals
Immunotherapy should not be withheld because of sex, age, or PS
From the Journals
Age, smoking among leading cancer risk factors for SLE patients
While older age was a risk factor for both breast and nonmelanoma skin cancers, use of antimalarial drugs lowered the risk of both.
From the Journals
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
A survey finds the COVID-19 pandemic to have a significant impact on oncologists’ decision-making.
Original Research
Scalp Wound Closures in Mohs Micrographic Surgery: A Survey of Staples vs Sutures
Limited data exist comparing staples and sutures for closing scalp wounds during Mohs micrographic surgery. The authors surveyed practicing Mohs...
Conference Coverage
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19
The mortality rate was 8% among patients who received immune checkpoint inhibitors, which is comparable with the overall mortality rate among...
Commentary
Risk Factors and Management of Skin Cancer Among Active-Duty Servicemembers and Veterans
Active-duty servicemembers of the US Military experience unique exposures that should be taken into consideration when determining their risk for...
News from the FDA/CDC
FDA approves triple drug combo for melanoma